[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,387,805
  • Shares Outstanding, K 102,879
  • Annual Sales, $ 139,740 K
  • Annual Income, $ -79,990 K
  • EBIT $ -372 M
  • EBITDA $ -365 M
  • 60-Month Beta 2.26
  • Price/Sales 24.15
  • Price/Cash Flow N/A
  • Price/Book 2.89

Options Overview Details

View History
  • Implied Volatility 83.48% (-2.65%)
  • Historical Volatility 72.82%
  • IV Percentile 51%
  • IV Rank 44.22%
  • IV High 122.94% on 02/11/26
  • IV Low 52.20% on 08/06/25
  • Expected Move (DTE 18) 4.81 (14.61%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 795
  • Volume Avg (30-Day) 1,047
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 18,676
  • Open Int (30-Day) 15,388
  • Expected Range 28.12 to 37.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.03
  • Number of Estimates 6
  • High Estimate $-0.95
  • Low Estimate $-1.16
  • Prior Year $-1.00
  • Growth Rate Est. (year over year) -3.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.87 +27.29%
on 05/19/26
34.38 -4.20%
on 05/11/26
+3.55 (+12.08%)
since 04/29/26
3-Month
21.63 +52.24%
on 03/30/26
34.38 -4.20%
on 05/11/26
+4.47 (+15.71%)
since 02/27/26
52-Week
15.35 +114.53%
on 05/30/25
36.44 -9.63%
on 01/12/26
+16.05 (+95.08%)
since 05/28/25

Most Recent Stories

More News
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license...

BEAM : 32.93 (+0.40%)
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently...

BEAM : 32.93 (+0.40%)
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.

BEAM : 32.93 (+0.40%)
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...

BEAM : 32.93 (+0.40%)
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...

BEAM : 32.93 (+0.40%)
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected...

BEAM : 32.93 (+0.40%)
Beam Therapeutics Reports Tomorrow, but the Pipeline Questions Linger Louder Than Ever

Barchart Research What to Expect from BEAM Earnings BEAM Generated May 4, 2026 Current Price $30.08 EPS Estimate $$-0.87 Consensus Rating Strong Buy Average Move 6.00% Beam Therapeutics Reports Tomorrow,...

BEAM : 32.93 (+0.40%)
3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets

BEAM : 32.93 (+0.40%)
CRSP : 56.18 (-0.35%)
MRK : 118.72 (-0.98%)
BMY : 57.18 (+0.47%)
NTLA : 14.07 (+2.85%)
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31...

BEAM : 32.93 (+0.40%)
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up...

BEAM : 32.93 (+0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 35.26
2nd Resistance Point 34.47
1st Resistance Point 33.70
Last Price 32.93
1st Support Level 32.14
2nd Support Level 31.35
3rd Support Level 30.58

See More

52-Week High 36.44
Last Price 32.93
Fibonacci 61.8% 28.38
Fibonacci 50% 25.90
Fibonacci 38.2% 23.41
52-Week Low 15.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.